- Stocks
- Healthcare
- NYSE: MRK

Price (delayed)

$124.38

Market cap

$315.03B

P/E Ratio

136.68

Dividend/share

$3.04

EPS

$0.91

Enterprise value

$343.67B

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the

The gross profit has grown by 9% year-on-year and by 3.8% since the previous quarter

The revenue has grown by 6% YoY and by 2.1% from the previous quarter

The P/E is 86% higher than the 5-year quarterly average of 73.4 but 49% lower than the last 4 quarters average of 268.8

Merck's equity has decreased by 14% YoY but it has increased by 7% from the previous quarter

The EPS has plunged by 82% YoY

The net income has dropped by 82% year-on-year

What are the main financial stats of MRK

Market
Valuations
Earnings

Shares outstanding

2.53B

Market cap

$315.03B

Enterprise value

$343.67B

Price to earnings (P/E)

136.68

Price to book (P/B)

7.8

Price to sales (P/S)

5.13

EV/EBIT

67.35

EV/EBITDA

38.32

EV/Sales

5.6

Revenue

$61.4B

EBIT

$5.1B

EBITDA

$8.97B

Free cash flow

$11.04B

Per share
Balance sheet
Liquidity

EPS

$0.91

Free cash flow per share

$4.36

Book value per share

$15.94

Revenue per share

$24.24

TBVPS

$26.49

Total assets

$105.85B

Total liabilities

$65.43B

Debt

$34.22B

Equity

$40.36B

Working capital

$6.35B

Debt to equity

0.85

Current ratio

1.25

Quick ratio

0.68

Net debt/EBITDA

3.19

Margins
Efficiency
Dividend

EBITDA margin

14.6%

Gross margin

74.4%

Net margin

3.8%

Operating margin

6.9%

Return on assets

2.2%

Return on equity

5.8%

Return on invested capital

7.2%

Return on capital employed

6.3%

Return on sales

8.3%

Dividend yield

2.44%

DPS

$3.04

Payout ratio

334.1%

How has the Merck stock price performed over time

Intraday

-1.04%

1 week

-0.85%

1 month

-4.85%

1 year

12.67%

YTD

14.09%

QTD

0.47%

How have Merck's revenue and profit performed over time

Revenue

$61.4B

Gross profit

$45.66B

Operating income

$4.25B

Net income

$2.31B

Gross margin

74.4%

Net margin

3.8%

MRK's net margin has dropped by 83% year-on-year

The net income has dropped by 82% year-on-year

Merck's operating income has soared by 81% from the previous quarter but it has plunged by 74% YoY

Merck's operating margin has surged by 77% QoQ but it has shrunk by 75% YoY

What is Merck's growth rate over time

What is Merck stock price valuation

P/E

136.68

P/B

7.8

P/S

5.13

EV/EBIT

67.35

EV/EBITDA

38.32

EV/Sales

5.6

The P/E is 86% higher than the 5-year quarterly average of 73.4 but 49% lower than the last 4 quarters average of 268.8

The EPS has plunged by 82% YoY

The price to book (P/B) is 16% higher than the 5-year quarterly average of 6.7 and 5% higher than the last 4 quarters average of 7.4

Merck's equity has decreased by 14% YoY but it has increased by 7% from the previous quarter

MRK's P/S is 9% above its 5-year quarterly average of 4.7 and 4.7% above its last 4 quarters average of 4.9

The revenue has grown by 6% YoY and by 2.1% from the previous quarter

How efficient is Merck business performance

The company's return on assets has shrunk by 82% YoY

Merck's ROE has plunged by 80% YoY

The ROIC has shrunk by 72% YoY but it has soared by 64% QoQ

The ROS has plunged by 70% YoY but it has soared by 66% from the previous quarter

What is MRK's dividend history

DPS

$3.04

Dividend yield

2.44%

Payout ratio

334.1%

Recent dividends

How did Merck financials performed over time

The total assets is 62% more than the total liabilities

MRK's quick ratio is down by 24% year-on-year

The current ratio has contracted by 13% YoY

MRK's debt is 15% smaller than its equity

The debt to equity has grown by 29% YoY but it has contracted by 9% from the previous quarter

Merck's equity has decreased by 14% YoY but it has increased by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.